TrialJAMA network open2024

COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical Trial.

Zhitao Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.